News
-
-
COMMUNIQUÉ DE PRESSE
BioNxt Receives Positive International Examination Report From the European Patent Office for Broad Patent Application for Sublingual Delivery of Anticancer Drugs for the Treatment of Autoimmune Neurodegenerative Diseases
BioNxt Solutions Inc. receives positive international examination report from the European Patent Office for sublingual delivery patent application. Company to expand patent portfolio for neurodegenerative diseases and MS market -
-
-
COMMUNIQUÉ DE PRESSE
BioNxt Signs Letter of Intent with Gen-Plus GmbH & Co KG for Potential Business Collaborations
BioNxt Solutions Inc. signs non-binding LOI with Gen-Plus GmbH & Co KG, part of Conscio Group, for potential cooperation in pharmaceutical products and clinical trials. Details to follow -
-
-
COMMUNIQUÉ DE PRESSE
BioNxt Signs Statement of Work with International Contract Research, Development, And Manufacturing Organization for Cladribine ODF Development
BioNxt Solutions Inc. signs agreement with German CRDMO for Cladribine oral dissolvable film development program targeting the lucrative multiple sclerosis market -
-
